Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems, MDS Win Patent Suit Against Micromass; Victors Awarded $47M

NEW YORK, March 15 - Applied Biosystems and MDS on Friday said they have won a patent infringement suit filed against Micromass UK and will walk away with $47.5 million in damages.

The Federal District Court in Wilmington, in Delaware, has ruled that Micromass' Quattro Ultima systems, which includes the MassTRANSIT version, infringe ABI's and MDS' US Patent No. 4,963,736.

According to a joint statement released by ABI and MDS, which together have a partnership called Applied Biosystems/MDS Sciex Instruments, the patent covers technology for "triple quadrupole mass spectrometers."

The court is expected to meet next week to enter the final judgment in the case, which was filed on Feb. 18, 2000.
"Our scientific leadership in the area of triple quadrupole mass spectrometry is the result of significant investments in research and development made over the last decade," Andy Boorn, president of MDS Sciex, the Toronto-based analytic instrumentation division of MDS.


Officials from Micromass were not available for comment.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.